635 related articles for article (PubMed ID: 23188792)
1. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S
J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
Vidaillac C; Leonard SN; Rybak MJ
Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
[TBL] [Abstract][Full Text] [Related]
3. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin.
Brinch KS; Tulkens PM; Van Bambeke F; Frimodt-Møller N; Høiby N; Kristensen HH
J Antimicrob Chemother; 2010 Aug; 65(8):1720-4. PubMed ID: 20534628
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
Sader HS; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2013 Jul; 57(7):3178-81. PubMed ID: 23629712
[TBL] [Abstract][Full Text] [Related]
5. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
Farrell DJ; Flamm RK; Sader HS; Jones RN
Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.
Kao TM; Wang JT; Weng CM; Chen YC; Chang SC
J Microbiol Immunol Infect; 2011 Oct; 44(5):346-51. PubMed ID: 21524980
[TBL] [Abstract][Full Text] [Related]
8. The effect of inoculum size on selection of in vitro resistance to vancomycin, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus.
Rio-Marques L; Hartke A; Bizzini A
Microb Drug Resist; 2014 Dec; 20(6):539-43. PubMed ID: 25010140
[TBL] [Abstract][Full Text] [Related]
9. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.
Sader HS; Flamm RK; Farrell DJ; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S181-6. PubMed ID: 22903950
[TBL] [Abstract][Full Text] [Related]
10. Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin.
Marconescu P; Graviss EA; Musher DM
Scand J Infect Dis; 2012 Aug; 44(8):620-2. PubMed ID: 22668202
[TBL] [Abstract][Full Text] [Related]
11. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis.
Lemaire S; Kosowska-Shick K; Julian K; Tulkens PM; Van Bambeke F; Appelbaum PC
Clin Microbiol Infect; 2008 Aug; 14(8):766-77. PubMed ID: 18727801
[TBL] [Abstract][Full Text] [Related]
12. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients.
Gonzalez N; Sevillano D; Alou L; Cafini F; Gimenez MJ; Gomez-Lus ML; Prieto J; Aguilar L
J Antimicrob Chemother; 2013 Oct; 68(10):2291-5. PubMed ID: 23674766
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
Steinkraus G; White R; Friedrich L
J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
[TBL] [Abstract][Full Text] [Related]
14. Bactericidal activity of daptomycin versus vancomycin in the presence of human albumin against vancomycin-susceptible but tolerant methicillin-resistant Staphylococcus aureus (MRSA) with daptomycin minimum inhibitory concentrations of 1-2microg/mL.
Torrico M; Giménez MJ; González N; Alou L; Sevillano D; Cafini F; Prieto J; Cleeland R; Aguilar L
Int J Antimicrob Agents; 2010 Feb; 35(2):131-7. PubMed ID: 20006469
[TBL] [Abstract][Full Text] [Related]
15. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.
Richter SS; Heilmann KP; Dohrn CL; Riahi F; Costello AJ; Kroeger JS; Biek D; Critchley IA; Diekema DJ; Doern GV
Antimicrob Agents Chemother; 2011 Sep; 55(9):4154-60. PubMed ID: 21709080
[TBL] [Abstract][Full Text] [Related]
16. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.
Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V
J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316
[TBL] [Abstract][Full Text] [Related]
18. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of daptomycin versus linezolid and vancomycin against gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections.
Wagenlehner FM; Lehn N; Witte W; Naber KG
Chemotherapy; 2005 May; 51(2-3):64-9. PubMed ID: 15870498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
